IMMUNEERING CORPORATION - CLASS A COMMON STOCK

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

14 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

12 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

11 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

05 мар 2024 17:00:00 Источник Nasdaq GlobeNewswire

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

04 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

01 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

20 фев 2024 08:00:01 Источник Nasdaq GlobeNewswire

Immuneering Announces Participation in February Investor Conferences

01 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

12 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

20 ноя 2023 16:05:00 Источник Nasdaq GlobeNewswire

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

09 ноя 2023 16:05:01 Источник Nasdaq GlobeNewswire

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

12 окт 2023 16:05:00 Источник Nasdaq GlobeNewswire

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

04 окт 2023 16:05:00 Источник Nasdaq GlobeNewswire

Immuneering to Present at the Morgan Stanley Healthcare Conference

06 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire

Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates

03 авг 2023 16:05:01 Источник Nasdaq GlobeNewswire

Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors

05 июн 2023 08:00:01 Источник Nasdaq GlobeNewswire

Immuneering to Present at the Jefferies Healthcare Conference

30 май 2023 08:00:01 Источник Nasdaq GlobeNewswire

Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

04 май 2023 16:05:02 Источник Nasdaq GlobeNewswire

Immuneering Announces $30 Million Underwritten Offering

18 апр 2023 09:24:15 Источник Nasdaq GlobeNewswire

Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline

18 апр 2023 09:00:02 Источник Nasdaq GlobeNewswire